Indivior PLC (NASDAQ:INDV) Receives Average Recommendation of “Moderate Buy” from Analysts

Indivior PLC (NASDAQ:INDV) has earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $39.3333.

Several equities analysts have recently commented on INDV shares. Northland Securities set a $50.00 target price on Indivior in a report on Tuesday, January 20th. Piper Sandler restated an “overweight” rating and set a $41.00 price objective (up from $27.00) on shares of Indivior in a research note on Friday, October 31st. HC Wainwright raised their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Morgan Stanley restated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th.

Insider Buying and Selling

In other Indivior news, Director Barbara Ryan bought 775 shares of the business’s stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. The trade was a 65.24% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel A. Ninivaggi purchased 775 shares of the company’s stock in a transaction on Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director directly owned 16,923 shares in the company, valued at $598,904.97. This represents a 4.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,871 shares of company stock valued at $172,385 in the last ninety days.

Institutional Trading of Indivior

Large investors have recently added to or reduced their stakes in the business. CWM LLC purchased a new position in Indivior in the 3rd quarter worth about $25,000. Quarry LP purchased a new position in shares of Indivior in the third quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior during the second quarter valued at approximately $26,000. Salomon & Ludwin LLC acquired a new stake in shares of Indivior during the fourth quarter valued at approximately $30,000. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Price Performance

Shares of INDV stock opened at $34.08 on Friday. The company’s fifty day moving average price is $34.95 and its two-hundred day moving average price is $28.93. The firm has a market capitalization of $4.26 billion, a P/E ratio of 37.04 and a beta of 0.80. Indivior has a 12 month low of $7.62 and a 12 month high of $38.00.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.